Cargando…

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

BACKGROUND: Signaling through mTOR and somatostatin pathway is implicated in thyroid cancer development. METHOD: We evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing on the in vitro and in vivo efficacy, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Owonikoko, Taofeek K., Zhang, Guojing, Lallani, Shenila B., Chen, Zhengjia, Martinson, Deborah E., Khuri, Fadlo R., Lonial, Sagar, Marcus, Adam, Sun, Shi-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390992/ https://www.ncbi.nlm.nih.gov/pubmed/30807575 http://dx.doi.org/10.1371/journal.pone.0206309

Ejemplares similares

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
por: Chen, Zhengjia, et al.
Publicado: (2013)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
por: Harvey, R. Donald, et al.
Publicado: (2020)

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
por: Owonikoko, Taofeek K., et al.
Publicado: (2016)

Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
por: Behera, Madhusmita, et al.
Publicado: (2011)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
por: Oh, You-Take, et al.
Publicado: (2015)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile
por: Chen, Zhengjia, et al.
Publicado: (2017)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
por: Khuri, Fadlo R.
Publicado: (2021)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer
por: Kudelka, Matthew R., et al.
Publicado: (2022)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Small Molecule Bax Agonists for Cancer Therapy
por: Xin, Meiguo, et al.
Publicado: (2014)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

caGrid-Enabled caBIG(TM) Silver Level Compatible Head and Neck Cancer Tissue Database System
por: Wang, Haibin, et al.
Publicado: (2010)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line
por: Gentilin, E., et al.
Publicado: (2023)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Pasireotide and octreotide in the treatment of severe late dumping syndrome
por: Mohammadi, Alireza, et al.
Publicado: (2017)

A prospective longitudinal study of Pasireotide in Nelson’s syndrome
por: Daniel, Eleni, et al.
Publicado: (2018)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Everolimus in Anaplastic Thyroid Cancer: A Case Series
por: Harris, Ethan J., et al.
Publicado: (2019)

Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies
por: Ojima, Hidenori, et al.
Publicado: (2016)

A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides
por: Du, Yuhong, et al.
Publicado: (2008)

Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017)

Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation
por: Attanasio, Roberto, et al.
Publicado: (2017)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
por: He, Xin, et al.
Publicado: (2020)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a2pe7uv3hag2dgumh8s5nib7hj